Antibodies containing two binding sites – bispecifics – are hot items these days generating a great deal of buzz in the industry. This is due to the fact that many of the new therapeutics now in development based on this technology hold much promise due to their synergistic effects conferred by binding two targets. Read More
Pexa-Vec (JX-594), developed by San Francisco-based Jennerex Inc., is a triple cancer killer. A publication in Cancer Research confirms anti-angiogenesis is part of Pexa-Vec's mechanism of action to attack tumors. Read More
NEW YORK – Last month's readout of Celgene Corp.'s successful Phase III study testing Abraxane (nab-paclitaxel) in combination with gemcitabine in pancreatic cancer is expected to change the standard of care for patients with metastatic disease, but its modest improvement in overall survival leaves plenty of room for new players in this notoriously difficult therapeutic space – assuming researchers can figure how to attack it. Read More
